Skip to main content

Table 3 Risk ratios for clinical outcomes according to quartiles of ANGPTL8

From: Predictive values of ANGPTL8 on risk of all-cause mortality in diabetic patients: results from the REACTION Study

Outcome   Control Diabetes
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Primary outcome
Death Q1 (Reference) 1 1 1 1 1 1
  Q2 (RR, 95% CI) 1.50 (0.25–9.08) 1.32 (0.21–8.52) 1.26 (0.20–8.03) 2.06 (0.76–5.59) 2.61 (0.90–7.59) 2.43 (0.83–7.16)
  Q3 (RR, 95% CI) 2.54 (0.49–13.23) 1.56 (0.28–8.70) 1.48 (0.27–8.23) 2.25 (0.84–6.05) 2.06 (0.72–5.86) 2.08 (0.72–6.02)
  Q4 (RR, 95% CI) 4.67 (1.00–21.92) 1.47 (0.28–7.64) 1.32 (0.25–7.06) 4.64 (1.86–11.59) 3.59 (1.36–9.51) 3.54 (1.32–9.50)
Secondary outcomes
  Q1 (Reference) 1 1 1 1 1 1
Q2 (RR, 95% CI) 1.44 (0.54–3.88) 1.26 (0.46–3.42) 1.21 (0.44–3.30) 1.05 (0.55–2.01) 1.07 (0.55–2.09) 1.05 (0.53–2.06)
Q3 (RR, 95% CI) 1.45 (0.54–3.90) 1.05 (0.38–2.87) 1.02 (0.37–2.80) 0.89 (0.46–1.74) 0.75 (0.38–1.51) 0.72 (0.35–1.45)
Q4 (RR, 95% CI) 2.57 (1.04–6.34) 1.28 (0.48–3.40) 1.19 (0.45–3.16) 1.72 (0.95–3.12) 1.30 (0.69–2.44) 1.20 (0.63–2.28)
MACE Q1 (Reference) 1 1 1 1 1 1
  Q2 (RR, 95% CI) 2.30 (0.70–7.60) 2.02 (0.61–6.73) 1.96 (0.58–6.56) 0.99 (0.47–2.10) 1.05 (0.48–2.28) 1.01 (0.46–2.21)
  Q3 (RR, 95% CI) 1.78 (0.51–6.18) 1.33 (0.38–4.70) 1.29 (0.36–4.57) 0.79 (0.36–1.73) 0.65 (0.29–1.48) 0.65 (0.29–1.49)
  Q4 (RR, 95% CI) 3.70 (1.19–11.44) 2.02 (0.61–6.72) 1.90 (0.57–6.27) 1.37 (0.68–2.77) 0.99 (0.48–2.08) 0.98 (0.46–2.09)
HF Q1 (Reference) 1 1 1 1 1 1
  Q2 (RR, 95% CI) 1.00 (0.06–16.02) 1.62 (0.07–38.32) 0.93 (0.04–23.90) 1.20 (0.36–4.00) 1.10 (0.32–3.78) 1.11 (0.32–3.83)
  Q3 (RR, 95% CI) 0.80 (0.21–3.01) 0.62 (0.16–2.40) 0.60 (0.15–2.40)
  Q4 (RR, 95% CI) 1.00 (0.06–16.10) 0.23 (0.01–5.84) 0.14 (0.01–4.21) 2.06 (0.69–6.13) 1.39 (0.45–4.30) 1.36 (0.43–4.32)
Renal dysfunction Q1 (Reference) 1 1 1 1 1 1
  Q2 (RR, 95% CI) 4.04 (0.45–36.50) 4.08 (0.45–37.01) 4.43 (0.47–41.99)
  Q3 (RR, 95% CI) 1.00 (0.14–7.17) 0.90 (0.12–6.75) 0.92 (0.12–7.15) 5.11 (0.59–44.13) 4.85 (0.56–42.13) 4.89 (0.53–44.95)
  Q4 (RR, 95% CI) 1.51 (0.25–9.13) 1.22 (0.16–9.26) 1.05 (0.13–8.54) 13.87 (1.80–107.12) 12.53 (1.59–98.90) 12.43 (1.48–104.81)
  1. Model 1 was unadjusted
  2. Model 2 was adjusted for age, sex and BMI
  3. Model 3 was adjusted for all variables in model 2 plus HDL, LDL, TG, cholesterol, duration of diabetes and treatment of diabetes in diabetes group
  4. MACE new-onset major adverse cardiovascular events, HF hospitalization for heart failure